You are here: Industry Insights > Novartis

News List

Novartis' SMA gene therapy Zolgensma could struggle to hit blockbuster territory fiercepharma
September 26, 2019
Novartis has been under pressure ever since the FDA approved Zolgensma in May, and news emerged in August that the company had included inaccurate data in the preclinical package it submitted to the agency.
Novartis to put AveXis into protective custody after data manipulation scandal fiercepharma
September 26, 2019
The Swiss drugmaker says not only will AveXis’ quality team be folded into its organization, it will happen as quickly as possible.
IFM Due signs immunotherapy deal with Novartis pharmaceutical-technology
September 10, 2019
IFM Due, a subsidiary of IFM Therapeutics, has entered a collaboration and exclusive option agreement with Novartis...
Novartis selling manufacturing site to Chinese drugmaker fiercepharma
September 08, 2019
Another Novartis ingredient operation is being hived off as the Swiss drugmaker continues its drive to lop off manufacturing jobs to improve margins. This time it is selling an operation in China that it opened 10 years ago.
Potential buyers size up Novartis site as layoffs loom for 400 workers fiercepharma
September 08, 2019
The clock is ticking down for the 400 workers at a Novartis plant which was put on the block last year as the company cuts costs to finance new therapies. There is some hope, however, with half a dozen companies taking a look at the U.K. site.
Novartis’s heart failure drug Entresto presents mixed trial results pharmaceutical-technology
September 04, 2019
Novartis has announced that its heart failure with reduced ejection fraction (HFrEF) drug Entresto (sacubitril/valsartan) has shown further efficacy in two Phase IV trials, PROVE-HF and EVALUATE-HF.
Greek prosecutors drop another inquiry in Novartis bribery case, but 3 remain open fiercepharma
September 02, 2019
Allegations that Novartis bribed top Greek officials may look even flimsier now that prosecutors have decided to toss out yet another line of inquiry. But the case isn’t dead yet.
Novartis’ CTL019 Applied for Clinical Trial in China to Officially Enter the Chinese Market PharmaSources/Xiaoyaowan
August 27, 2019
Novartis develops the world’s first CAR T-cell therapy CTL019. And now the drug has been accepted by the CDE.
Ousted AveXis CSO denies wrongdoing in Novartis data scandal, taps Elon Musk lawyer fiercepharma
August 22, 2019
Novartis’ AveXis has already fired its former chief scientific officer Brian Kaspar in connection with the Zolgensma data manipulation scandal.
Novartis names Bulto new U.S. pharma chief as exec reshuffle continues fiercepharma
August 15, 2019
Novartis’ leadership shakeup under CEO Vas Narasimhan has led to a new U.S. pharmaceutical chief.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page